

## AMENDMENTS TO THE CLAIMS

This listing of claims replaces all prior versions, and listings, of claims in the application.

### Listing of Claims

1. (Currently Amended) A method for stimulating bone formation and/or inhibiting bone resorption in humans or animals comprising the administration to a subject in need thereof of a composition comprising The use of oleuropein compound or a derivative thereof for making a composition to be used for stimulating bone formation and/or for inhibiting bone resorption for humans or animals.
2. (Currently amended) The method use according to claim 1, wherein the ~~characterized in that said~~ composition is a nutritional composition suitable for oral administration.
3. (Currently amended) The method use according to claim 2 wherein the ~~characterized in that said said nutritional composition is to be used for stimulating bone formation for~~ subject in need thereof is a young individuals being in a growth period.
4. (Currently amended) The method use according to claim 2, wherein the subject in need thereof seeks to prevent ~~characterized in that said nutritional composition is to be used for preventing~~ bone loss which occurs with aging.
5. (Currently amended) The method use according to claim 2, wherein the subject in need thereof has a disorder associated with unbalanced bone formation- bone resorption ratio or seeks to prevent a disorder associated with unbalanced bone formation-bone resorption ratio ~~characterized in that said nutritional composition is to~~

~~be used for preventing or treating disorders associated with an unbalanced bone formation bone resorption ratio.~~

6. (Currently amended) The method use according to claim 2, wherein the subject in need thereof has a bone deficiency resulting from a fracture characterized in that said nutritional composition is to be used for treating a bone deficiency resulting from a fracture.

7. (Currently amended) The method use according to claim 2, wherein the subject in need thereof is suffering from or might suffer from a condition selected characterized in that said nutritional composition is to be used for preventing or for treating conditions from the group consisting of type I or type II osteoporosis, secondary osteoporosis, Paget's disease, bone loss or osteolysis observed at the vicinity of a prosthesis, metastatic bone diseases, cancer induced hypocalcemia, multiple myeloma, periodontal diseases or osteoarthritis.

8. (Currently amended) The method use according to claim 2, wherein the characterized in that said nutritional composition is selected from the group consisting of comes as food compositions and beverages, comprising juices (fruits or vegetables), oils, butters, margarines, vegetal fats, cans (for example tuna fish in oil), soups, milk-based preparations (yogurts, cottage cheese), ice creams, cheeses (for example oil-kept cheeses), baked products (such as bread, cookies and cakes), puddings, confectionary products, cereal bars, breakfast cereals, condiments, seasoning products (especially spices and dressings).

9. (Currently amended) The method use according to claim 2, wherein the  
~~characterized in that said~~ nutritional composition ~~is comes as~~ a product for animal  
feeding, in a wet, half-wet, or dry form.
10. (Currently amended) The method use according to claim 2, wherein  
~~characterized in that the oleuropein compound or one derivative thereof comes as an~~  
is an extraction product from a plant belonging to the *Oleaceae* family.
11. (Currently amended) The method use according to claim 10, wherein  
~~characterized in that~~ the extraction product is a product extracted from the stems, the  
leaves, the fruits or the stones of a plant belonging to the *Oleaceae* family.
12. (Currently amended) The method use according to claim 10, wherein  
~~characterized in that the~~ plant belonging to the *Oleaceae* family is selected from the  
group consisting of *olea europaea*, a plant of genus *Ligustrum*, a plant of genus  
*Syringa*, a plant of genus *Fraxinus*, a plant of genus *Jasminum*, and a plant of genus  
*Osmanthus*.
13. (Currently amended) The method use according to claim 10, wherein  
~~characterized in that~~ the extraction product is an olive oil or an oleuropein rich extract  
olive oil or leaves.
14. (Currently amended) The method use according to claim 2, wherein the  
~~characterized in that said~~ nutritional composition is orally administered daily suitable  
~~for the daily oral administration~~ in an amount ranging from 0.01 to 200 mg of the  
oleuropein ~~compound~~ or ~~one~~ derivative thereof.

15. (Currently amended) ~~A nutritional~~ Nutritional composition for stimulating bone formation and/or inhibiting bone resorption, ~~which characterized in that it comprises, as active nutritional compound, the oleuropein compound or a one derivative thereof.~~
16. (Currently amended) The method use according to claim 1, wherein the ~~characterized in that said composition is a human or animal pharmaceutical composition.~~
17. (Currently amended) The method use according to claim 16, wherein the ~~subject in need thereof is a characterized in that said pharmaceutical composition is to be used for stimulating bone formation for the young individual being in a the growth period.~~
18. (Currently amended) The method use according to claim 16, wherein the ~~subject in need thereof seeks to prevent characterized in that said pharmaceutical composition is to be used for preventing bone loss that occurs with aging (ostopenia).~~
19. (Currently amended) The method use according to claim 16, wherein the ~~subject in need thereof has a pathology associated with an unbalanced bone formation-bone resorption ratio or seeks to prevent characterized in that said pharmaceutical composition is to be used for preventing or treating a pathology associated with an unbalanced bone formation-bone resorption ratio.~~
20. (Currently amended) The method use according to claim 16, wherein the ~~subject in need thereof has characterized in that said pharmaceutical composition is to be used for treating a bone deficiency resulting from a fracture.~~

21. (Currently amended) The method use according to claim 16, wherein the subject in need thereof is suffering from or might suffer from a condition selected ~~characterized in that said composition is to be used for preventing or treating a~~ pathology from the group consisting of type I or type II osteoporosis, secondary osteoporosis, Paget's disease, bone loss or osteolysis observed at the vicinity of a prosthesis, metastatic bone diseases, cancer induced hypercalcemia, multiple myeloma, periodontal diseases or osteoarthritis.
22. (Currently amended) The method use according to claim 16, wherein the ~~characterized in that said~~ pharmaceutical composition is in a suitable form for oral, parenteral, intramuscular or intravenous administration.
23. (Currently amended) The method use according to claim 16, wherein the ~~characterized in that said~~ pharmaceutical composition is suitable for a daily oral administration in an amount ranging from 0.01 to 200 mg of the oleuropein ~~compound~~ or ~~one~~ derivative thereof.
24. (Currently amended) A human ~~Human~~ or animal pharmaceutical composition for stimulating bone formation and/or for inhibiting bone resorption, comprising ~~characterized in that it comprises as active compound the~~ oleuropein ~~compound~~ or ~~a~~ ~~one~~ derivative thereof.
25. (New) The method according to claim 8, wherein the nutritional composition is selected from the group consisting of fruit juices, vegetable juices, oils, butters, margarines, vegetal fats, canned foods, soups, milk-based-foods, ice creams, cheeses,

baked products, puddings, confectionary products, cereal bars, breakfast cereals, condiments, and seasoning products.

26. (New) The method according to claim 25, wherein the nutritional composition is selected from the group consisting of tuna fish in oil, yogurts, cottage cheese, oil-kept cheeses, bread, cookies and cakes, spices and dressings.